124 related articles for article (PubMed ID: 19299090)
41. TRIM39R, but not TRIM39B, regulates type I interferon response.
Kurata R; Tajima A; Yonezawa T; Inoko H
Biochem Biophys Res Commun; 2013 Jun; 436(1):90-5. PubMed ID: 23707810
[TBL] [Abstract][Full Text] [Related]
42. The validity of the pathergy test (non-specific skin hyperreactivity) in Behçet's disease: a double-blind study by independent observers.
Altaç M; Tüzün Y; Yurdakul S; Binyildiz P; Yazici H
Acta Derm Venereol; 1982; 62(2):158-9. PubMed ID: 6179342
[No Abstract] [Full Text] [Related]
43. Percutaneous intralesional injection of calcitonin and methylprednisolone for treatment of an aneurysmal bone cyst at C-2.
Ohashi M; Ito T; Hirano T; Endo N
J Neurosurg Pediatr; 2008 Nov; 2(5):365-9. PubMed ID: 18976109
[TBL] [Abstract][Full Text] [Related]
44. The close association between dental and periodontal treatments and oral ulcer course in behcet's disease: a prospective clinical study.
Karacayli U; Mumcu G; Simsek I; Pay S; Kose O; Erdem H; Direskeneli H; Gunaydin Y; Dinc A
J Oral Pathol Med; 2009 May; 38(5):410-5. PubMed ID: 19320802
[TBL] [Abstract][Full Text] [Related]
45. Auto-inflammatory syndromes and oral health.
Scully C; Hodgson T; Lachmann H
Oral Dis; 2008 Nov; 14(8):690-9. PubMed ID: 19193198
[TBL] [Abstract][Full Text] [Related]
46. Cognitive functioning in Behçet's disease.
Cavaco S; da Silva AM; Pinto P; Coutinho E; Santos E; Bettencourt A; Pinto C; Gonçalves A; Silva S; Gomes F; Carvalho L; Pereira C; Martins B; Correia J; Vasconcelos C
Ann N Y Acad Sci; 2009 Sep; 1173():217-26. PubMed ID: 19758154
[TBL] [Abstract][Full Text] [Related]
47. Molecular physiology and pharmacology of calcitonin.
Huang CL; Sun L; Moonga BS; Zaidi M
Cell Mol Biol (Noisy-le-grand); 2006 Sep; 52(3):33-43. PubMed ID: 17535752
[TBL] [Abstract][Full Text] [Related]
48. Cerebrovascular manifestations of Behçet's disease.
Ilhan D; Gulcan E; Uzuner N; Celikkas E
J Clin Neurosci; 2009 Apr; 16(4):576-8. PubMed ID: 19231193
[TBL] [Abstract][Full Text] [Related]
49. Cerebral venous thrombosis in Behçet's disease.
Saadoun D; Wechsler B; Resche-Rigon M; Trad S; Le Thi Huong D; Sbai A; Dormont D; Amoura Z; Cacoub P; Piette JC
Arthritis Rheum; 2009 Apr; 61(4):518-26. PubMed ID: 19333987
[TBL] [Abstract][Full Text] [Related]
50. [Neuro-Behçet: clinicopathological findings in an autopsy case].
Landeyro J; Vidaur-Tello L; García-Fontgivell JF; Elguezábal A; Gené-Hijós M; Mayayo-Artal E
Rev Neurol; 2008 Dec 1-15; 47(11):575-8. PubMed ID: 19048537
[TBL] [Abstract][Full Text] [Related]
51. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease.
Park KS; Baek JA; Do JE; Bang D; Lee ES
Tissue Antigens; 2009 Sep; 74(3):222-7. PubMed ID: 19563524
[TBL] [Abstract][Full Text] [Related]
52. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome.
Kiliç H; Zeytin HE; Korkmaz C; Mat C; Gül A; Coşan F; Dinç A; Simşek I; Süt N; Yazici H
Rheumatology (Oxford); 2009 Nov; 48(11):1388-91. PubMed ID: 19717547
[TBL] [Abstract][Full Text] [Related]
53. Renal involvement in Behcet's disease.
Ardalan MR; Sadreddini S; Noshad H; Ebrahimi A; Molaeefard M; Somi MH; Shoja MM
Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):618-22. PubMed ID: 19587503
[TBL] [Abstract][Full Text] [Related]
54. Clinical aspects of Behcet's syndrome in Brazil: a review of 16 cases.
Tunes RS; Amorim R; Santiago MB
Acta Reumatol Port; 2009; 34(2A):235-40. PubMed ID: 19474778
[TBL] [Abstract][Full Text] [Related]
55. The pathophysiology of calcitonin in man.
Passeri M; Palummeri E; Pedrazzoni M; Cervellin G; Barbagallo M; Butturini L; Di Ruvo R
Int J Tissue React; 1986; 8(3):255-60. PubMed ID: 3781766
[TBL] [Abstract][Full Text] [Related]
56. Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers.
Cheon JH; Kim ES; Shin SJ; Kim TI; Lee KM; Kim SW; Kim JS; Kim YS; Choi CH; Ye BD; Yang SK; Choi EH; Kim WH
Am J Gastroenterol; 2009 Oct; 104(10):2492-9. PubMed ID: 19532129
[TBL] [Abstract][Full Text] [Related]
57. Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy.
Kappen JH; Mensink PB; Lesterhuis W; Lachman S; van Daele PL; van Hagen PM; van Laar JA
Am J Gastroenterol; 2008 Dec; 103(12):3213-4. PubMed ID: 19086980
[No Abstract] [Full Text] [Related]
58. Treatment of neuro-Behçet's disease: an update.
Borhani Haghighi A
Expert Rev Neurother; 2009 Apr; 9(4):565-74. PubMed ID: 19344307
[TBL] [Abstract][Full Text] [Related]
59. A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease.
Houwen TBV; Hagen PMV; Kappen JH; Kuijpers RWAM; Daele PLAV; Dik WAV; Laar JAMV
Asian Pac J Allergy Immunol; 2022 Dec; 40(4):435-441. PubMed ID: 32828115
[TBL] [Abstract][Full Text] [Related]
60. [Functional state of calcitonin-producing cells of the female rats' thyroid as a result of experimental osteopenia therapy by graduated support loading combined with oestrogens and calcitonin injection].
Loginov VI
Aviakosm Ekolog Med; 2005; 39(6):33-7. PubMed ID: 16536031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
